Suzhou Smartnuclide Biopharmaceutical Company was founded in 2015, our aim is to provide innovative diagnostic and therapeutic radiopharmaceuticals for patients around the world. Our products focus on thyroid cancer, precision radioactive imaging and targeted radioligand therapy. Since its foundation, Smart Nuclide has raised over 200 million yuan with four rounds of venture capital investment.
In Smart Nuclide, we build several technology platforms focusing on the discovery, R&D, and production of radiopharmaceuticals based on single-domain antibody, with independent intellectual property rights. Based on our proprietary technology platforms, we have prospectively formed a robust and competitive portfolio of pipelines with more than 10 innovative radioactive diagnostic and therapeutic products.
Our first product, recombinant human thyroid stimulating hormone (SNA001), designed to raise the levels of TSH during the Radioactive iodine (RAI) therapy has submitted the Biologics License Application (BLA) to Center for Drug Evaluation (CDE). If approved, SNA001 will be the first and only rhTSH product in Mainland China.
Multiple innovative radioactive imaging pipelines targeting solid tumors are expected to enter clinical trial soon. Our first independently developed radioactive diagnostic agent targeting PD-L1 (SNA002) has received the authorization of Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) and Center for Drug Evaluation (CDE).
SmartNuclide